Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Valsartan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 205Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Macleods`s Generics Valsartan, HCTZ Receives Approval in US
    Macleods`s Generics Valsartan, HCTZ Receives Approval in US

    07 Jan 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207299

    FDA
    07 Jan 2025
    Share Share
    Novartis loses latest bid to block generic version of blockbuster heart drug
    Novartis loses latest bid to block generic version of blockbuster heart drug

    17 Oct 2024

    // REUTERS

    https://www.reuters.com/legal/litigation/novartis-loses-latest-bid-block-generic-version-blockbuster-heart-drug-2024-10-16/

    REUTERS
    17 Oct 2024
    Share Share
    USV launches heart failure medication at 8rs per 50mg tablet
    USV launches heart failure medication at 8rs per 50mg tablet

    15 Oct 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/usv-launches-heart-failure-medication-at-rs-8-per-50mg-tablet/

    EXPRESSPHARMA
    15 Oct 2024
    Share Share
    Macleods`s Generics Amlodipine, Valsartan Receives Approval in US
    Macleods`s Generics Amlodipine, Valsartan Receives Approval in US

    11 Oct 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207292

    FDA
    11 Oct 2024
    Share Share
    Novartis loses initial bid to block generic of best-selling heart drug
    Novartis loses initial bid to block generic of best-selling heart drug

    13 Aug 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-loses-initial-bid-block-generic-best-selling-heart-drug-2024-08-12/

    REUTERS
    13 Aug 2024
    Share Share
    Zenara's Generics Valsartan Receives Approval in US
    Zenara's Generics Valsartan Receives Approval in US

    05 Aug 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218169

    FDA
    05 Aug 2024
    Share Share